At the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, from September 30 to October 3, Kenvue's subsidiaries—Neutrogena, Aveeno, and Regaine—shared research on the effectiveness of key ingredients in skin and hair care products, including niacinamide, trehalose, colloidal oat, and 5% minoxidil.
Read More
The studies highlighted Neutrogena’s innovations in multifunctional sun care and Aveeno’s colloidal oat formulations. A particular focus was on how these ingredients can improve skin barrier health, address visible skin issues, and promote hair regrowth. Kate Stockman, Vice President and Head of EMEA R&D at Kenvue, emphasized that these advancements contribute to consumer well-being and confidence.
In sun care, Neutrogena's Ultra Sheer Invisible Fluid Sunscreen Oil Control SPF 50+ was shown to benefit oily and acne-prone skin. Research involving two small multi-ethnic Brazilian populations revealed a 56% reduction in visible redness and a 46% decrease in acne-related hyperpigmentation after 28 days. Notably, 90% of participants reported less oiliness, and skin hydration increased by 13%.
Another study on Neutrogena’s Ultra Sheer Invisible Fluid Sunscreen Hydration Fluid SPF 50 indicated a 22% improvement in skin hydration among women with dry skin. Participants also reported better skin tone uniformity, with over 90% noticing increased moisture after daily use for 28 days.
Aveeno presented findings on its colloidal oat formulation, focusing on skin recovery following UV exposure. The research demonstrated that Aveeno’s proprietary Triple Oat Complex enhances the production of skin barrier proteins and supports recovery after sun damage. An international survey of 178 dermatologists revealed that 87.6% consistently recommend a colloidal oat-based emollient alongside corticosteroids for eczema management, citing benefits in skin barrier integrity and moisture.
Regaine reported that early intervention in hair loss treatment could lead to better regrowth results with 5% minoxidil. Its research on male androgenetic alopecia showed that younger men and those in earlier stages of hair loss had better outcomes. A post-hoc analysis of a Phase III clinical trial found that men aged 20 to 30 experienced an average increase of 26.25 hairs after 16 weeks of treatment, while men over 30 saw an average increase of 19.93 hairs. Improvements in hair regrowth were statistically significant across various stages of hair loss, reinforcing the potential of timely intervention.